Genmab A/S (GNMSF) EBITDA (2018 - 2026)
Genmab A's (GNMSF) quarterly EBITDA came in at $180.0 million in Q1 2026, down 4.26% YoY from $188.0 million in Q1 2025, and down 82.13% on a QoQ basis from $1.0 billion in Q3 2025.
Genmab A/S (GNMSF) EBITDA (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 6 years of EBITDA data on file, last reported at $180.0 million in Q1 2026.
- Quarterly EBITDA fell 4.26% year-over-year to $180.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 45.9% YoY) and the FY2025 annual result came in at $1.1 billion, up 9.57% from the prior year.
- EBITDA slipped to $180.0 million in Q1 2026, from $1.0 billion in the prior quarter.
- In the past five years, EBITDA ranged from a high of $1.0 billion in Q3 2025 to a low of $116.0 million in Q1 2024.
- A 3-year average of $436.1 million and a median of $352.0 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2025 — EBITDA surged 62.07% — and 2026, when it dropped 4.26%.
- Tracing GNMSF's EBITDA over 3 years: stood at $662.0 million in 2024, then surged by 52.11% to $1.0 billion in 2025, then sank by 82.13% to $180.0 million in 2026.
- The last three EBITDA figures came in at $180.0 million (Q1 2026), $1.0 billion (Q3 2025), and $548.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 375.00 Mn |
| Mar 31, 2026 | 180.00 Mn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 548.00 Mn |
| Mar 31, 2025 | 188.00 Mn |
| Sep 30, 2024 | 662.00 Mn |
| Jun 30, 2024 | 352.00 Mn |
| Mar 31, 2024 | 116.00 Mn |
| Sep 30, 2020 | -49.00 |
| Dec 31, 2019 | 691.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |